Treatment of experimental renal osteodystrophy with pamidronate

13Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We evaluated the effects of the bisphosphonate pamidronate on bone histomorphometry, structure and strength in male rats with uninephrectomy or with chronic renal disease induced by 5/6 nephrectomy. In rats with chronic renal disease the plasma urea, phosphate and parathyroid hormone levels were significantly increased compared to rats with a uninephroctomy and none of these parameters was affected by pamidronate treatment. In the femoral midshaft, chronic renal disease reduced cortical bone mineral density and content. No difference was observed in the breaking load of the femoral midshaft. In the distal femur, a high-turnover renal osteodystrophy was found but pamidronate suppressed this bone turnover and increased bone mineral content. Treatment had no effect on chronic disease-induced augmentation of osteoid volume or fibroblast surface. These studies show that in this model of stage 3 renal disease, pamidronate increased mineral content in the femoral midshaft and distal metaphysis primarily by adding bone to endocortical and trabecular surfaces but did not reduce osteitis fibrosa. © 2008 International Society of Nephrology.

Cite

CITATION STYLE

APA

Jokihaara, J., Pörsti, I. H., Kööbi, P., Jolma, P. M., Mustonen, J. T., Saha, H. H. T., … Järvinen, T. L. N. (2008). Treatment of experimental renal osteodystrophy with pamidronate. Kidney International, 74(3), 319–327. https://doi.org/10.1038/ki.2008.180

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free